- Home
- Publications
- Publication Search
- Publication Details
Title
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 12, Issue 6, Pages 801-804
Publisher
Informa Healthcare
Online
2013-07-29
DOI
10.1517/14740338.2013.823947
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-TNF-α Inhibitors: A New Therapeutic Approach for Inflammatory Immune-Mediated Diseases: An Update upon Efficacy and Adverse Events
- (2017) G. Murdaca et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Efficacy and Safety of Leflunomide or Methotrexate plus Subcutaneous Tumour Necrosis Factor-Alpha Blocking Agents in Rheumatoid Arthritis
- (2017) M. Benucci et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Selective TNF-α inhibitor-induced injection site reactions
- (2013) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Effects of TNF-α inhibitors upon the mechanisms of action of VEGF
- (2013) Giuseppe Murdaca et al. Immunotherapy
- Endothelial dysfunction in rheumatic autoimmune diseases
- (2012) Giuseppe Murdaca et al. ATHEROSCLEROSIS
- Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study
- (2012) Raoul Bergner et al. CLINICAL RHEUMATOLOGY
- Determination of Lymphotoxin-Alpha Levels in Patients with Psoriatic Arthritis Undergoing Etanercept Treatment
- (2012) Giuseppe Murdaca et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate
- (2012) Sang-Won Lee et al. ARTHRITIS RESEARCH & THERAPY
- Eficácia terapêutica e segurança de metotrexato + leflunomida em pacientes colombianos com artrite reumatoide ativa refratária ao tratamento convencional
- (2012) John Londono et al. Revista Brasileira De Reumatologia
- Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events
- (2011) Giuseppe Murdaca et al. AUTOIMMUNITY REVIEWS
- Update upon efficacy and safety of TNF-α inhibitors
- (2011) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases
- (2011) Giuseppe Murdaca et al. Internal and Emergency Medicine
- Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare
- (2010) Giuseppe Murdaca et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
- (2010) J. Sokolove et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Leflunomide in the treatment of patients with early rheumatoid arthritis—results of a prospective non-interventional study
- (2010) Herbert Kellner et al. CLINICAL RHEUMATOLOGY
- Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease
- (2009) Eugene Y Chiang et al. NATURE MEDICINE
- Vascular effects of biologic agents in RA and spondyloarthropathies
- (2009) Zoltán Szekanecz et al. Nature Reviews Rheumatology
- Serum vascular endothelial growth factor and sublingual immunotherapy
- (2008) G. Ciprandi et al. ALLERGY
- Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study)
- (2008) Barbara Maria Colombo et al. AUTOIMMUNITY REVIEWS
- Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus
- (2008) Giorgio Ciprandi et al. HUMAN IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started